LivaNova PLC stock surged to a new 52-week high, trading at $73.31. The price reflects a robust 62.95% gain over the past year.
The medical technology company, with a market cap of $4.01 billion, delivered a 34% return over the last six months.
Four analysts recently revised their earnings estimates upward. Revenue growth stands at 12.4%.
In Q1 2026, LivaNova beat expectations with adjusted EPS of $0.98 (vs. $0.90 estimate) and revenue of $362.3 million (vs. $346.06 million estimate).
